Hsbc Holdings PLC Vertex Pharmaceuticals Inc Call Options Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

Call Options

24 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $9.02 Million - $9.91 Million	-19,600 Reduced 63.43%	11,300 $5.26 Million
Q2 2024 Aug 12, 2024	SELL	$392.81 - $485.53 $2.55 Million - $3.16 Million	-6,500 Reduced 17.38%	30,900 $14.5 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $5.91 Million - $6.47 Million	14,500 Added 63.32%	37,400 $15.6 Million
Q4 2023 Feb 12, 2024	SELL	$343.0 - $410.68 $4.77 Million - $5.71 Million	-13,900 Reduced 37.77%	22,900 $9.32 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $6.43 Million - $6.89 Million	19,000 Added 106.74%	36,800 $12.8 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $3.05 Million - $3.41 Million	-9,700 Reduced 35.27%	17,800 $6.26 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $679,752 - $775,440	-2,400 Reduced 8.03%	27,500 $8.66 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $1.17 Million - $1.32 Million	4,100 Added 15.89%	29,900 $8.63 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.51 Million - $1.68 Million	5,500 Added 27.09%	25,800 $7.52 Million
Q2 2022 Aug 11, 2022	BUY	$234.96 - $292.55 $3.36 Million - $4.18 Million	14,300 Added 238.33%	20,300 $5.73 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $3.45 Million - $4.07 Million	-15,600 Reduced 72.22%	6,000 $1.57 Million
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $1.61 Million - $2.03 Million	9,100 Added 72.8%	21,600 $4.74 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $1.56 Million - $1.75 Million	8,600 Added 220.51%	12,500 $2.28 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $168,741 - $198,990	900 Added 30.0%	3,900 $786,000
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $248,424 - $289,572	-1,200 Reduced 28.57%	3,000 $644,000
Q4 2020 Feb 25, 2021	SELL	$207.01 - $276.09 $3.11 Million - $4.14 Million	-15,000 Reduced 78.13%	4,200 $992,000
Q3 2020 Nov 12, 2020	SELL	$255.65 - $303.1 $2.4 Million - $2.85 Million	-9,400 Reduced 32.87%	19,200 $5.24 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $9.09 Million - $11.9 Million	-40,300 Reduced 58.49%	28,600 $8.3 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $1.66 Million - $2.06 Million	-8,300 Reduced 10.75%	68,900 $16.3 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $10.7 Million - $14.3 Million	63,900 Added 480.45%	77,200 $16.8 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $2.04 Million - $2.3 Million	12,300 Added 1230.0%	13,300 $2.25 Million
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $724,284 - $837,628	-4,400 Reduced 81.48%	1,000 $183,000
Q1 2018 May 11, 2018	SELL	$151.6 - $177.13 $1.52 Million - $1.77 Million	-10,000 Reduced 64.94%	5,400 $880,000
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $2.28 Million - $2.5 Million	15,400	15,400 $2.34 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$10.9 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$9.45 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$8.7 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$4.82 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$3.67 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account